Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen Gets CE Mark for QuantideX NGS Oncology Panel

NEW YORK (GenomeWeb) — Asuragen said today that it has obtained CE marking for its new QuantideX next-generation sequencing oncology panel for the detection of clinically relevant variants.

The QuantideX NGS DNA Hotspot 21 kit is designed for use on the Illumina MiSeq platform and screens for 21 of the most commonly observed genomic variants across a variety of cancers including non-small cell lung cancer, colorectal cancer, and melanoma. It is available for research use only in the US.

Earlier this year, Asuragen announced expanded CE marking for its multiplexed QuantideX qPCR BCR-ABL IS kit and its QuantideX qPCR BCR-ABL minor kit.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.